Pulse.

a daily field guide to health research that matters

◆ Console

‹ Fri · 6 Nov 2026
Standard addition

Serum sodium and chloride interplay and the effect of empagliflozin in heart failure: an EMPEROR-Pooled analysis.

Chloride measurement improves heart-failure risk prediction, though it doesn't change whether sodium-glucose inhibitors help patients.

A pooled trial analysis examined serum sodium and chloride as prognostic markers and treatment modifiers in ambulatory heart failure. Chloride added prognostic information, but electrolyte status did not alter the observed benefit of empagliflozin.

What the study was

Study design
Pooled secondary analysis of randomized heart-failure trials
Population
Ambulatory patients with heart failure in the EMPEROR trials
Category
Treatment Innovation
Maturity
Validated
Journal
Clinical research in cardiology : official journal of the German Cardiac Society

Why it surfaced

Large trial-derived clinical data refine heart-failure risk interpretation and support consistent SGLT2 benefit.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.